Analysis – Goldea Capital

Temenos Launches Embedded AI Capabilities to Help Banks Move Faster, Stay in Control, and Create Better Experiences

Written by Customer Service on May 7, 2026. Posted in Public Companies.

New Temenos AI agents, copilots and conversational studio embed intelligence into the trusted core of banking GRAND-LANCY, Switzerland and COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced new AI-powered product capabilities launching at Temenos Community Forum (TCF) 2026. The new releases include Temenos AI Agents, Copilots and Conversational Studio embedded across Temenos’ Core and Digital Banking products, as well as its Financial Crime Mitigation (FCM) solution. These launches demonstrate Temenos’ continued execution against the product pillar of its AI strategy, which focuses on embedding intelligence into the trusted platform banks rely on to run their most critical operations. The new AI capabilities unveiled at TCF 2026 include:Conversational...

Apollo Funds Complete Acquisition of Prosol Group

Written by Customer Service on May 7, 2026. Posted in Mergers And Acquisitions.

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds (the “Apollo Funds”) have completed the previously announced acquisition of a majority stake in Prosol Group (“Prosol” or the “Company”), the multi-specialist in fresh food businesses and food retail in France, from Ardian, a global private investment firm. Prosol’s existing minority shareholders and management team have reinvested alongside the Apollo Funds. Founded in 1992, Prosol has differentiated itself by building a proprietary, vertically integrated supply chain, sourcing fresh, quality products resulting in a highly loyal and fast-growing customer base. Prosol operates and/or supplies nearly 450 stores across France under two main banners, Grand Frais and fresh. Chief Executive Officer Jean-Paul Mochet will continue to...

Valeo – Voting rights – April 2026

Written by Customer Service on May 7, 2026. Posted in Public Companies.

PRESS RELEASEParis, 07 May, 2026 Information on the total number of voting rightsand shares forming the share capital(Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of the French Financial Markets Authority)Date Issued capital Par value Total number of shares Total number of voting rightsTheoretical* Exercisable** April 30, 2026 € 245,607,624 € 1 245,607,624 276,338,794 273,674,945*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.**The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.About...

Suominen Corporation’s Interim Report for January 1 – March 31, 2026: Profitability improvement program underway

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

Suominen Corporation’s Interim Report on May 7, 2026, at 9:30 a.m. (EEST) Suominen Corporation’s Interim Report for January 1 – March 31, 2026: Profitability improvement program underway KEY FIGURES 1-3/ 1-3/ 1-12/ 2026 2025 2025Net sales, EUR million 95.6 117.5 412.4Comparable EBITDA, EUR million 2.2 4.1 12.6Comparable EBITDA, % 2.3 3.5 3.1EBITDA, EUR million -0.3 4.1 11.3EBITDA, % -0.3 3.5 2.7Comparable operating profit / loss, EUR million -1.9 -0.3 -4.2Comparable operating profit / loss, % -2.0 -0.2 -1.0Operating profit / loss, EUR million -4.4 -0.3 -5.9Operating profit / loss, % -4.4 -0.2 -1.4Profit / loss for the period, EUR million -5.7 -2.2 -12.1Cash flow from operations, EUR million 4.5 -0.4 12.2Cash flow from operations per share, EUR 0.08 -0.01 0.21Earnings per share, basic, EUR -0.10 -0.04 -0.21Return...

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

Written by Customer Service on May 7, 2026. Posted in Public Companies.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (“Agreement”) with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private Limited (collectively, Hetero). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Hetero’s Abbreviated...

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Written by Customer Service on May 7, 2026. Posted in Mergers And Acquisitions.

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma’s entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage...

Financial Calendar 2026 – update

Written by Customer Service on May 7, 2026. Posted in Public Companies.

ANNOUNCEMENTA.P. Møller – Mærsk A/S – Financial Calendar 2026 – updateThe interim report for the 2nd quarter will be published on 13 August 2026 and not on 6 August 2026 as previously stated in the Company’s financial calendar. The Company’s financial calendar for the remainder of 2026 is as follows:A.P. Møller – Mærsk A/S plans to publish itsInterim Report for the 2nd quarter on 13 August 2026 Interim Report for the 3rd quarter on 5 November 2026Copenhagen, 7 May 2026 Contact person: Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484 Page 1 of 1AttachmentFinancial Calendar 2026 – update

Shell plc First Quarter 2026 Interim Dividend

Written by Customer Service on May 7, 2026. Posted in Dividend Reports And Estimates.

London, May 7, 2026 − The Board of Shell plc (the “Company”) (XLON: SHEL, XNYS: SHEL, XAMS: SHELL) today announced an interim dividend in respect of the first quarter of 2026 of US$ 0.3906 per ordinary share. Details relating to the first quarter 2026 interim dividendPer ordinary share(GB00BP6MXD84) Q1 2026Shell Shares (US$) 0.3906Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling. An alternative ‘Electronic Election Entitlement’ (‘EEE’) process is available in CREST for dividends with options elections. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros. Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members))...

Solar A/S: Nr. 11 2026 Q1 results at the lower end of our expected range

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

March showed growth across most markets, while Q1 performance came in at the lower end of expectations, impacted by severe winter in February.. CEO Jens Andersen says:“Q1 revenue and EBITDA were at the lower end of our expected range, primarily due to the severe winter, particularly in February, which impacted activity levels, most notably in our infrastructure business. The impact eased in March, when revenue growth was delivered across most markets. Several suppliers have announced significant price increases, primarily affecting oil-based products. For Solar, this may lead to higher cyclical inventory gains in the short term, while also potentially having a negative impact on demand. The integration of Sonepar Norge is ahead of schedule, with integration costs DKK 10m lower than initially expected, and our logistics centre in...

Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2026: The volume of new loans began to increase – capital adequacy continued to strengthen – the comparable profit before tax for the first quarter improved to EUR 13.7 million

Written by Customer Service on May 7, 2026. Posted in Earnings Releases And Operating Results.

Released: 07.05.2026 Category: Interim Report OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 MAY 2026 AT 8.45 A.M. EEST, INTERIM REPORT Q1 Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2026: The volume of new loans began to increase – capital adequacy continued to strengthen – the comparable profit before tax for the first quarter improved to EUR 13.7 million This release is a summary of Oma Savings Bank’s (OmaSp) January-March 2026 Interim Report, which can be read from the pdf file attached to this stock exchange release and on the Company’s web pages www.omasp.fi CEO Karri Alameri: The year 2026 opened in an operating environment characterised by geopolitical tension, moderate economic growth and uncertainty in the financial markets. Relatively low market interest rates are continuing to put pressure on banks’ net interest income,...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals